This bill was last introduced in the 41st Parliament, 2nd Session, which ended in August 2015.
Rona Ambrose Conservative
This bill has received Royal Assent and is now law.
This is from the published bill.
This enactment amends the Food and Drugs Act regarding therapeutic products in order to improve safety by introducing measures to, among other things,
(a) strengthen safety oversight of therapeutic products throughout their life cycle;
(b) improve reporting by certain health care institutions of serious adverse drug reactions and medical device incidents that involve therapeutic products; and
(c) promote greater confidence in the oversight of therapeutic products by increasing transparency.
All sorts of information on this bill is available at LEGISinfo, an excellent resource from the Library of Parliament. You can also read the full text of the bill.
(Bill C-17. On the Order: Government Orders:)
June 13, 2014—Report stage of Bill C-17, An Act to amend the Food and Drugs Act—the Minister of Health.
Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)Routine Proceedings
Conservative
Terence Young Conservative Oakville, ON
Mr. Speaker, there have been consultations with respect to the final stages of Bill C-17, Vanessa's law, and I believe you would find the unanimous consent of the House for the following motion. I move:
That, notwithstanding any Standing Order or usual practices of this House, Bill C-17, An Act to amend the Food and Drugs Act, shall be deemed concurred in at the report stage and deemed read a third time and passed.
The Speaker Andrew Scheer
Does the hon. member have the unanimous consent of the House to propose the motion?
Some hon. members
Agreed.
The Speaker Andrew Scheer
The House has heard the terms of the motion. Is it the pleasure of the House to adopt the motion?
Some hon. members
Agreed.
The Speaker Andrew Scheer
(Motion agreed to, bill reported, concurred in, read the third time and passed)